Literature DB >> 8253949

Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee.

S Hammer1, C Crumpacker, R D'Aquila, B Jackson, J Lathey, D Livnat, P Reichelderfer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8253949      PMCID： PMC265936          DOI： 10.1128/jcm.31.10.2557-2564.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  46 in total

1.  HIV antigen detection in circulating immune complexes.

Authors:  L Kestens; G Hoofd; P L Gigase; R Deleys; G van der Groen
Journal:  J Virol Methods       Date:  1991-01       Impact factor: 2.014

2.  Rapid and quantitative detection of enzymatically amplified HIV-1 DNA using chemiluminescent oligonucleotide probes.

Authors:  C Y Ou; S H McDonough; D Cabanas; T B Ryder; M Harper; J Moore; G Schochetman
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

3.  A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals.

Authors:  P Nishanian; K R Huskins; S Stehn; R Detels; J L Fahey
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

4.  Isolation of HIV-1 from the blood of seropositive adults: patient stage of illness and sample inoculum size are major determinants of a positive culture. The Walter Reed Retroviral Research Group.

Authors:  D S Burke; A K Fowler; R R Redfield; S Dilworth; C N Oster
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

5.  A semiquantitative microassay for measurement of relative number of blood mononuclear cells infected with human immunodeficiency virus.

Authors:  P Gupta; A Enrico; J Armstrong; M Doerr; M Ho; C Rinaldo
Journal:  AIDS Res Hum Retroviruses       Date:  1990-10       Impact factor: 2.205

6.  High-level viremia in adults and children infected with human immunodeficiency virus: relation to disease stage and CD4+ lymphocyte levels.

Authors:  M S Saag; M J Crain; W D Decker; S Campbell-Hill; S Robinson; W E Brown; M Leuther; R J Whitley; B H Hahn; G M Shaw
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

7.  Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic western blot. Evidence from a cohort of homosexual men.

Authors:  S M Wolinsky; C R Rinaldo; S Kwok; J J Sninsky; P Gupta; D Imagawa; H Farzadegan; L P Jacobson; K S Grovit; M H Lee
Journal:  Ann Intern Med       Date:  1989-12-15       Impact factor: 25.391

8.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.

Authors:  P Simmonds; P Balfe; J F Peutherer; C A Ludlam; J O Bishop; A J Brown
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

9.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245
View more
  17 in total

1.  Standardized peripheral blood mononuclear cell culture assay for zidovudine susceptibility testing of clinical human immunodeficiency virus type 1 isolates: effect of reducing the numbers of replicates and concentrations.

Authors:  I C Marschner; D L Mayers; A Erice; L Smeaton; V A Johnson; D D Richman; P Reichelderfer; A J Japour
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

2.  Deterioration of detectable human immunodeficiency virus serum p24 antigen in samples stored for batch testing.

Authors:  J L Lathey; I C Marschner; B Kabat; S A Spector
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group.

Authors:  W A Scott; D Brambilla; E Siwak; C Beatty; J Bremer; R W Coombs; H Farzadegan; S A Fiscus; S M Hammer; F B Hollinger; N Khan; S Rasheed; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

4.  Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories.

Authors:  B Yen-Lieberman; D Brambilla; B Jackson; J Bremer; R Coombs; M Cronin; S Herman; D Katzenstein; S Leung; H J Lin; P Palumbo; S Rasheed; J Todd; M Vahey; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

5.  Optimization of quantitative culture assay for human immunodeficiency virus from plasma. Plasma Viremia Group Laboratories of the AIDS Clinical Trials Group (National Institute of Allergy and Infectious Diseases).

Authors:  J L Lathey; S A Fiscus; S Rasheed; J C Kappes; B P Griffith; T Elbeik; S A Spector; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

6.  Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay.

Authors:  Cheryl Jennings; Susan A Fiscus; Suzanne M Crowe; Aleksandra D Danilovic; Ralph J Morack; Salvatore Scianna; Ada Cachafeiro; Donald J Brambilla; Jorg Schupbach; Wendy Stevens; Richard Respess; Oliviero E Varnier; Gary E Corrigan; J Simon Gronowitz; Michael A Ussery; James W Bremer
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

7.  Detection of vertical transmission of human immunodeficiency virus type 1 by a commercial polymerase chain reaction assay.

Authors:  P Bermúdez; P Moreno; R Delgado; J T Ramos; J Ruiz-Contreras; A R Noriega
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

8.  Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.

Authors:  A M Caliendo; A Savara; D An; K DeVore; J C Kaplan; R T D'Aquila
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Quantitative analysis of syncytium-inducing and non-syncytium-inducing virus in patients infected with human immunodeficiency virus type 1.

Authors:  R W Shafer; E Aguiniga; T C Merigan
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

10.  Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load.

Authors:  B Weiser; S Nachman; P Tropper; K H Viscosi; R Grimson; G Baxter; G Fang; C Reyelt; N Hutcheon; H Burger
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.